HIV Action Plan for England: £170m to reduce new diagnoses and re-engage people in care – but are targets achievable?
1 December 2025. Related: Special reports, Treatment access, HIV prevention and transmission, Activism & advocacy.
2025
Future meetings and webinars 2026
1 December 2025. Related: Future meetings.
America First: does global strategy undermine recent US pledge to Global Fund?
1 December 2025. Related: Special reports, Treatment access, Activism & advocacy.
The international impact of US policies on HIV: news from AVAC’s Global Health Watch
29 November 2025. Related: Early access, Activism & advocacy.
UNAIDS calls for continued global solidarity, funding, human rights and community leadership to overcome the 2025 funding crisis
25 November 2025. Related: Early access, Treatment access, Activism & advocacy.
Importance of rapid PEP: predicting impact of delay and duration of 2- and 3-drug PEP
23 November 2025. Related: Journal scan, HIV prevention and transmission.
Case of functional cure reported in an elite controller after 22 years without ART
23 November 2025. Related: Journal scan, Cure-related research.
Lenacapavir drug resistance: rapid switching and the need for resistance testing
23 November 2025. Related: Journal scan, Antiretrovirals, Drug resistance.
Australian survey reports limited interest in CAB-LA PrEP by gay and bisexual men
22 November 2025. Related: Journal scan, Treatment access, HIV prevention and transmission.
Anti-vaccine propaganda added to US CDC website
22 November 2025. Related: Treatment access, Activism & advocacy.
Global Fund announces $11.3 billion in pledges for 8th round of funding: still $7 billion short
22 November 2025. Related: Treatment access, Activism & advocacy.
Sleep disorders and quality of sleep added to EACS management guidelines
6 November 2025. Related: Conference reports, Guidelines, Coinfections and complications.
Europe is missing HIV targets but EACS now recommends event-based PrEP for all using 2:1:1 or 2:7 dosing
27 October 2025. Related: Special reports, Conference reports, HIV prevention and transmission.
Recent mpox transmissions in Europe of clade 1b in gay men: New ECDC assessment brief
24 October 2025. Related: mpox.
BHIVA guidelines for adults (2025 interim update)
22 October 2025. Related: Guidelines.
EACS guidelines major update: ART, OIs, on-demand PrEP for women, weight gain, HIV-2, pregnancy, infant feeding, sleep disorders and more
21 October 2025. Related: Conference reports.
EACS 2025: Community declaration highlights HIV care for migrant communities
20 October 2025. Related: Conference reports.
20th European AIDS Conference (EACS 2025)
17 October 2025. Related: Conference reports.
NICE approves limited access to injectable cabotegravir PrEP in England and Wales + BHIVA notes on prescribing
17 October 2025. Related: Treatment access, HIV prevention and transmission.
Latest UK HIV statistics: 42% of diagnoses are late and disparities in care continue by ethnicity
9 October 2025. Related: Special reports, Other news.
US guidelines updated: new section on metabolic complications (2025)
30 September 2025. Related: Guidelines.
Featured UK PrEP booklets now available
23 September 2025. Related: HIV prevention and transmission, Activism & advocacy.
UN80 plans to dismantle UNAIDS by 2026: sign-on against this now
22 September 2025. Related: Activism & advocacy.
IAS 2025 conference now open access
21 September 2025. Related: Conference reports, On the web.
Lenacapavir injectable PrEP approved in Europe – UK application later in 2025
19 September 2025. Related: Antiretrovirals, HIV prevention and transmission.
New BASHH report on PrEP access and uptake in the UK
16 September 2025. Related: HIV prevention and transmission, On the web.
IAS 2025: Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)
8 August 2025. Related: Conference reports, Treatment strategies, Guidelines, Coinfections and complications.
IAS 2025: Induced stress can increase HIV dynamics
7 August 2025. Related: Conference reports, Cure-related research, Basic science and immunology.
Switching to long-acting injectable ART with detectable viral load in people struggling with oral ART
6 August 2025. Related: Antiretrovirals, Treatment strategies, Drug resistance.
Featured IAS 2025: WHO guidelines: major updates on injectables, AHD, breastfeeding, infant prophylaxis and peer support
2 August 2025. Related: Conference reports, Guidelines.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
31 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research
31 July 2025. Related: Conference reports, Treatment access, Coinfections and complications, Cancer and HIV, Activism & advocacy, Research studies.
Latest news on US crisis (24 July): Plans to end PEPFAR
29 July 2025. Related: Treatment access, Activism & advocacy.
IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort
28 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa
27 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
People living with HIV still excluded from 75% of pivotal cancer studies
27 July 2025. Related: Cancer and HIV.
IAS 2025: Increases in reports of HIV criminalisation cases globally
26 July 2025. Related: Conference reports, Activism & advocacy.
Plans to transition US HIV treatment guidelines (DHHS)
25 July 2025. Related: Guidelines.
Lenacapavir on track for PrEP approval in Europe: questions on access
25 July 2025. Related: Antiretrovirals, HIV prevention and transmission.
IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results
20 July 2025. Related: Conference reports, Antiretrovirals.
IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.
IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that could stop HIV
17 July 2025. Related: Conference reports, Treatment strategies.
Signal that sliver of PEPFAR might be salvaged
16 July 2025. Related: Treatment access, Activism & advocacy.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.
Call to drop abacavir from use in adults
13 July 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Coinfections and complications.
IAS 2025: HIV care is political: early focus on the funding crisis
12 July 2025. Related: Conference reports, Treatment access.
IAS 2025: HIV cure research at IAS 2025
12 July 2025. Related: Conference reports.
Global Fund plans for lenacapavir PrEP in selected countries
9 July 2025. Related: Treatment access, HIV prevention and transmission.
Featured AIDS quilts at the Tate: reflection and call for action
8 July 2025. Related: In memory, Special reports.
US government has altered more than 100 scientific databases since 20 January
5 July 2025. Related: Treatment alerts, Activism & advocacy.
Latest news on US crisis (3 July): legal challenges, Global Fund, WHO, Kigali conference
5 July 2025. Related: Treatment access, Activism & advocacy.
Phase 2/3 studies put on hold for two once-weekly Gilead compounds
3 July 2025. Related: Antiretrovirals.
UK PrEP 2025 guidelines online
2 July 2025. Related: Guidelines, HIV prevention and transmission.
Why the new HIV PrEP guidelines from the UK are so exciting (2025)
2 July 2025. Related: Special reports, Guidelines, HIV prevention and transmission.
Latest on US crisis (26 June): Global Fund, GAVI and RFK Jr
2 July 2025. Related: Treatment access, Activism & advocacy.
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
1 July 2025. Related: Antiretrovirals, HIV prevention and transmission.
Latest on US crisis (13 June): legal and organisational responses
1 July 2025. Related: Treatment access, Activism & advocacy.
HIV organisations support trans and non-binary communities against the unworkable EHRC guidance
1 July 2025. Related: Treatment access, Activism & advocacy.
Featured UK HIV care for transgender and non-binary people: EHRC guidance is unworkable
1 July 2025. Related: Special reports, Treatment access, Activism & advocacy.
IAS 2025: Kigali Call to Action: sign-on to global leaders
1 July 2025. Related: Conference reports.
UK guidelines on doxyPEP to prevent syphilis and gonorrhoea vaccine to become available in England
17 June 2025. Related: Guidelines, Coinfections and complications.
APBI calls for greater participant diversity in industry studies
15 June 2025. Related: Activism & advocacy, Research studies.
Risk of metabolic syndrome when starting ART with bictegravir vs dolutegravir
7 June 2025. Related: Journal scan, Side effects, Weight, diabetes, metabolic complications.